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Relation Between Blood Pressure and Clinical Outcome in
Hypertensive Subjects With Previous Stroke
Chan Joo Lee, MD, PhD;* Jinseub Hwang, PhD;* Jaewon Oh, MD, Sang-Hak Lee, MD, PhD; Seok-Min Kang, MD, PhD; Hyeon Chang Kim,
MD, PhD; Sungha Park, MD, PhD
Background-—This study investigated whether a mean blood pressure (BP) of <130/80 mm Hg is associated with further
reduction in cardiovascular outcomes in treated hypertensive subjects with previous stroke.
Methods and Results-—Subjects from the Korea National Health Insurance Service health examinee cohort diagnosed as having
stroke and hypertension from January 1st, 2003 and December 31st, 2006 (N=2320) were grouped according to mean systolic
(<130, 130–<140, and ≥140 mm Hg) and diastolic (<80, 80–<90, and ≥90 mm Hg) BP recorded during follow-up health
examinations. All-cause and cardiovascular mortality over 11 years were compared. Compared with subjects with a systolic BP of
≥140 mm Hg (N=736), subjects with a systolic BP of 130 to <140 mm Hg (N=793) had a signiﬁcantly lower risk of all-cause death
(hazard ratio [HR], 0.61; 95% conﬁdence interval [CI], 0.47–0.79; P<0.001), cardiovascular mortality (HR, 0.39; 95% CI, 0.25–0.61;
P<0.001), and fatal ischemic stroke (HR, 0.25; 95% CI, 0.10–0.63; P=0.003). Systolic BP of <130 mm Hg (N=791) was associated
with lower risk of nonfatal hemorrhagic stroke. Subjects with a diastolic BP of 80 to <90 mm Hg (N=1100) had signiﬁcantly lower
risk of all-cause death (HR, 0.60, 95% CI, 0.45–0.80; P<0.001) and cardiovascular mortality (HR, 0.45; 95% CI, 0.30–0.70;
P<0.001) than those with a diastolic BP of ≥90 mm Hg (N=342). Diastolic BP of <80 mm Hg (N=878) was associated with
reduced risk of nonfatal hemorrhagic stroke and further lowering of all-cause mortality and cardiovascular mortality.
Conclusions-—BP of <130/80 mm Hg was associated with improved outcomes in hypertensive subjects with previous stroke.
( J Am Heart Assoc. 2017;6:e007102. DOI: 10.1161/JAHA.117.007102.)
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R ecently, the SPRINT (Systolic Blood Pressure Interven-tion Trial) demonstrated that the treatment goal of
systolic blood pressure (SBP) of <120 mm Hg was superior
to the SBP goal of <140 mm Hg in reducing cardiovascular
risk.1 Although the SPRINT study included subjects with high
cardiovascular risk, it excluded hypertensive subjects with
previous stroke based on the SPS3 (Secondary Prevention of
Small Subcortical Strokes) trial, an open-label randomized
study that demonstrated the beneﬁt of strict SBP lowering in
subjects with previous lacunar infarction.2 Compared with
subjects randomized to a target SBP of 130 to 149 mm Hg,
subjects randomized to a lower SBP target of <130 mm Hg
demonstrated a nonsigniﬁcant reduction in the primary
outcome of all strokes and a signiﬁcantly lower rate of
intracerebral hemorrhage.2 Consequently, the American
Stroke Association proposes the IIb recommendation for a
target SBP of 130 mm Hg in subjects with previous lacunar
infarction.3 However, the SPS3 study was limited by its
inclusion of only subjects with previous lacunar infarction,
relative lack of statistical power, 2-by-2 multifactorial design,
and enrollment of both normotensive and hypertensive
subjects. Therefore, whether strict SBP lowering is beneﬁcial
for all hypertensive subjects with previous stroke is unclear.
However, it is difﬁcult to verify this through large-scale
clinical studies, so using observational cohort data may be
helpful.4
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The present study aimed to evaluate whether lower mean
BP in hypertensive subjects with previous stroke has a
beneﬁcial effect on reducing cardiovascular events, using the
National Health Insurance Service (NHIS) cohort.
Methods
Study Population
This study used the NHIS health examinee cohort, compris-
ing 514 866 individuals randomly selected from the NHIS
health examination database in 2002.5 The NHIS cohort
proﬁle was previously reported.6 The NHIS provides free
health examinations to eligible NHIS members aged
≥40 years. Detailed information about the health examina-
tion is described in Data S1. The intellectual property right
of this database belongs to the National Health Insurance
corporation. As such, we are not authorized to open the
database to the public. However, any investigator can apply
for use of the database because it has been open to the
public for research purpose (https://nhiss.nhis.or.kr/). This
cohort was followed up for 11 years until 2013. The cohort
data consisted of qualiﬁcations; medical service claims;
pharmacy claims; and health examination ﬁndings, including
anthropometric data, blood chemistry, urine analysis, chest
radiography, and information about lifestyle and personal
and familial history of hypertension. The disposition of the
study cohort is shown in Figure 1. We selected subjects
who had been diagnosed as having stroke (Korean Classi-
ﬁcation of Disease [KCD] codes I60–I64), requiring hospi-
talization, and hypertension (KCD codes I10–I13) between
January 1, 2003 and December 31, 2006 for inclusion in the
study population. The KCD system is based on and similar
to the International Classiﬁcation of Diseases, Tenth Revision
(ICD-10).7 Stroke was classiﬁed into hemorrhagic stroke
(KCD codes I60–I62), ischemic stroke (KCD code I63), and
unspeciﬁed stroke (KCD code I64). Subjects diagnosed as
having stroke and hypertension either simultaneously or
separately during the index period were included; 1337 of
the subjects received a diagnosis of hypertension before the
diagnosis of stroke. Individuals diagnosed as having a
previous or active malignancy (KCD codes C00–C97) after
stroke diagnosis were excluded. In addition, individuals with
prescription records for antihypertensive medications for
<1 year during the follow-up or who had undergone health
examination only once between January 1, 2003 and
December 31, 2013 were excluded. Ultimately, 2320
individuals were included in the analysis. The Institutional
Review Board of Yonsei University Health System approved
the study (Institutional Review Board number 4-2016-1043),
with waiver of informed consent because this was a
retrospective observational study of an anonymized data
set.
Deﬁnition of Medication History
Information about medications during the follow-up was
obtained using a prescription database after the index date.
We categorized the 5 ﬁrst-line antihypertensive agents into 4
classes: renin-angiotensin system blocker; b-blocker; calcium
channel blocker; and diuretics, including hydrochlorothiazide,
chlortalidone, and metolazone. Subjects who had prescrip-
tion data for antihypertensive agents for at least 1 year were
assumed to be taking the medication. The ﬁrst prescription
date and total prescription duration of each medication were
obtained from the prescription database. Only individuals
who had taken antihypertensive agents for at least 1 year
during follow-up were included. In addition, subjects who
had taken aspirin or a statin for at least 1 year were
assumed to be taking these medications for secondary
stroke prevention. Diabetes mellitus was deﬁned as a
diagnosis of diabetes mellitus (KCD codes E11–E14) with
prescription data for antidiabetic medications before the
diagnosis of stroke.8 Atrial ﬁbrillation was determined by the
presence of the corresponding diagnostic code (KCD code
I48).
BP Measurement and Classiﬁcation
BP was measured in hospitals and clinics certiﬁed as medical
health examination centers by the Korean National Health
Insurance Corporation. The measurement protocol was for
brachial BP after 5 minutes of rest in the sitting position. BP
measurement was repeated if the ﬁrst measurement was
Clinical Perspective
What Is New?
• In a cohort of hypertensive subjects with previous stroke, a
mean blood pressure (BP) of <130/80 mm Hg had optimal
beneﬁt in terms of mortality, cardiovascular mortality, and
nonfatal hemorrhagic stroke.
• However, diastolic BP of <80 mm Hg was associated with
signiﬁcantly higher rate of nonfatal myocardial infarction
compared with a diastolic BP of 80 to <90 mm Hg.
What Are the Clinical Implications?
• The results from this study may provide insight into the
possible beneﬁt of strict diastolic BP lowering in hyperten-
sive subjects with previous stroke in terms of mortality
reduction.
• However, the increased risk of myocardial infarction with
strict diastolic BP lowering should be considered as well.
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>120/80 mm Hg. BP was measured by qualiﬁed medical
personnel at each health examination center. Both automatic
oscillometric devices and mercury sphygmomanometers were
used for BP measurements. The choice of device was left to
the discretion of individual examination centers, with the
preferred recommendation for a mercury sphygmomanometer
until 2015, when the sale of mercury sphygmomanometers
was banned.
We deﬁned strict SBP control as mean SBP of <130 mm Hg,
consistent with the SPS3 study. Although diastolic BP (DBP) of
<90 mm Hg is recommended in the current guidelines, studies
using J curves have indicated that cardiovascular risk increases
at<60 to 70 mm Hg.9,10 Therefore, we also aimed to determine
whether DBP lowering at <80 mm Hg was beneﬁcial in
poststroke hypertensive subjects.
The mean value of BP at all health examinations during the
follow-up was used to determine the BP target that subjects
had achieved. The study population was divided into 3 groups
according to observed mean SBP and DBP: (1) mean SBP of
<130 mm Hg (N=791), 130 to <140 mm Hg (N=793), and
≥140 mm Hg (N=736); and (2) mean DBP of <80 mm Hg
(N=878), 80 to <90 mm Hg (N=1100), and ≥90 mm Hg
(N=342).
Follow-Up and Outcome Measurement
The mean and median follow-up duration were 2987757 and
3092 days (interquartile range, 2151- 3468 days), respec-
tively. The primary outcomes were all-cause mortality and
cardiovascular mortality. The dates and causes of death were
obtained from the qualiﬁcation data in the cohort database,
which was prepared by Statistics Korea. Clinical outcomes
were assessed after the diagnosis of stroke. Cardiovascular
mortality was deﬁned as death from a circulatory system
disease (KCD codes I00–I99). Causes of cardiovascular
mortality were further categorized as myocardial infarction
(MI; KCD codes I21–I23), hemorrhagic stroke (KCD codes
I60–I62), and ischemic stroke (KCD code I63).11 We also
analyzed rates of nonfatal MI and nonfatal stroke requiring
hospitalization. We deﬁned nonfatal stroke as rehospitaliza-
tion with either nonfatal hemorrhagic or ischemic stroke as
the major diagnosis, according to KCD code.
Statistical Analysis
Household income was categorized as upper 20%, middle 40%,
and lower 40% based on income levels provided by the NHIS.
Residential areas were classiﬁed as metropolitan cities or
Figure 1. The disposition of the study cohort. DB indicates database; and MI, myocardial infarction.
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Table 1. Clinical Characteristics of the Total Study Population According to Observed Mean SBP (N=2320)
Characteristics
Observed Mean SBP, mm Hg
P Value<130 (N=791) 130–<140 (N=793) ≥140 (N=736)
Types of stroke 0.377
Hemorrhagic 158 (20.0) 139 (17.5) 144 (19.6)
Ischemic 606 (76.6) 619 (78.1) 571 (77.6)
Unspecified 27 (3.4) 35 (4.4) 21 (2.9)
SBP, mm Hg 122.75.8 134.32.8 149.29.0 <0.001
No. of BP measurements 4.61.9 4.71.9 3.91.8 <0.001
Age, y 59.19.0 60.69.1 62.49.1 <0.001
Sex 0.136
Male 430 (54.4) 437 (55.1) 435 (59.1)
Female 361 (45.6) 356 (44.9) 301 (40.9)
Residential area 0.118
Metropolitan 281 (35.5) 243 (30.6) 246 (33.4)
Province 510 (64.5) 550 (69.4) 490 (66.6)
Household income 0.005
Upper 20% 249 (31.5) 208 (26.2) 178 (24.2)
Middle 40% 309 (39.1) 300 (37.8) 294 (39.9)
Lower 40% 233 (29.5) 285 (35.9) 264 (35.9)
Smoking status 0.572
Never smoker 517 (65.4) 546 (68.9) 504 (68.5)
Ex-smoker 62 (7.8) 57 (7.2) 57 (7.7)
Current smoker 212 (26.8) 190 (24.0) 175 (23.8)
Alcohol frequency 0.133
Never 492 (62.2) 500 (63.1) 447 (60.7)
2–3 Drinks/mo 96 (12.1) 79 (10.0) 68 (9.2)
1–2 Drinks/wk 93 (11.8) 86 (10.8) 94 (12.8)
3–4 Drinks/wk 64 (8.1) 59 (7.4) 57 (7.7)
Daily 46 (5.8) 69 (8.7) 70 (9.5)
Body mass index, kg/m2 24.32.9 24.43.0 24.43.1 0.781
Total cholesterol, mg/dL 206.644.4 206.543.2 204.342.1 0.530
Fasting glucose, mg/dL 106.453.0 104.135.6 114.262.8 <0.001
Baseline SBP, mm Hg 127.814.3 139.015.2 155.519.0 <0.001
Baseline DBP, mm Hg 80.010.3 85.111.2 92.112.8 <0.001
History of DM 46 (5.8) 47 (5.9) 51 (6.9) 0.614
History of atrial fibrillation 31 (3.9) 19 (2.4) 8 (1.1) 0.002
Medications during follow-up
RASBs 536 (67.8) 566 (71.4) 519 (70.5) 0.263
RASB duration, d 1580.51201.7 1618.91193.0 1605.41218.3 0.836
b-Blockers 202 (25.5) 221 (27.9) 234 (31.8) 0.024
b-Blocker duration, d 1023.21189.8 901.61024.2 931.21052.8 0.278
CCBs 540 (68.3) 591 (74.5) 576 (78.3) <0.001
Continued
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provinces. Group differences in continuous variables were
analyzed by using 1-way analysis of variance. Categorical
variables were summarized as numbers and percentages of the
total group and compared by v2 test. The effects of BP on all-
cause mortality and cardiovascular mortality were analyzed by
using Kaplan-Meier curves. The association between BP and
clinical events, including both fatal and nonfatal outcomes, was
evaluated by using Cox proportional hazard models with the
covariate adjustment method using the propensity scores,
because some end points had a rare event problem when we
used the multivariate Cox proportional hazard model with all
confounders. The effect of each level of BP on mortality and
clinical events was determined by comparison to the uncon-
trolled hypertension group (SBP ≥140 mm Hg or DBP
≥90 mm Hg). We also compared the effect of each BP level
on mortality and clinical events by comparison to the SBP of
130 to <140 mm Hg and DBP of 80 to <90 mm Hg groups.
Propensity scores were assigned using multinomial logistic
regression for groups stratiﬁed by mean SBP and DBP based on
age, sex, residential area, household income, smoking status,
alcohol frequency, body mass index, total cholesterol, fasting
glucose, baseline SBP, baseline DBP, diabetes mellitus history,
and atrial ﬁbrillation history. Medication exposure was not
included to estimate propensity score because it is information
of medication after the index date. Instead, a subgroup analysis
was conducted for aspirin or statin users (Tables S1 and S2)
and subjects without baseline atrial ﬁbrillation (Tables S3 and
S4). In addition, we analyzed the subject regardless of duration
of antihypertensive medication (Tables S5 and S6).
All statistical analyses were performed using R statistical
software, version 3.3.0 (R Foundation for Statistical
Computing, Vienna, Austria). All tests were 2 sided, and
statistical signiﬁcance was deﬁned as P<0.05.
Results
Demographic Data
Clinical characteristics of the study population, according to
mean SBP and DBP grouping, are shown in Tables 1 and 2.
The proportions of ischemic stroke and hemorrhagic stroke
were 77.4% and 19.8%, respectively. Previous stroke type did
not differ according to mean SBP group. The SBP of
<130 mm Hg group included a higher percentage of subjects
with atrial ﬁbrillation and a signiﬁcantly lower proportion of
subjects taking b-blockers, calcium channel blockers, and
diuretics. Although the percentage of subjects taking aspirin
and statins during the follow-up did not signiﬁcantly differ,
there was a higher percentage of warfarin users among
subjects with an SBP of <130 mm Hg.
Unlike mean SBP, subjects with a higher mean DBP had a
higher percentage with hemorrhagic stroke. The group with a
mean DBP of <80 mm Hg had a signiﬁcantly lower percent-
age of subjects taking calcium channel blockers and diuretics
and a signiﬁcantly higher percentage of subjects taking
aspirin, statins, and warfarin.
Clinical Outcomes According to Mean SBP and
DBP
Kaplan-Meier analyses for all-cause death and cardiovascular
death, according to mean SBP and DBP, revealed signiﬁcantly
Table 1. Continued
Characteristics
Observed Mean SBP, mm Hg
P Value<130 (N=791) 130–<140 (N=793) ≥140 (N=736)
CCB duration, d 1668.71266.7 1749.21224.0 1782.91288.5 0.227
Diuretics 171 (21.6) 240 (30.3) 212 (28.8) <0.001
Diuretic duration, d 782.6896.9 863.1909.3 779.0869.7 0.325
Statins 362 (45.8) 340 (42.9) 297 (40.4) 0.102
Statin duration, d 1357.11069.6 1351.41086.1 1210.41028.0 0.068
Aspirin 368 (46.5) 340 (42.9) 322 (43.8) 0.314
Aspirin duration, d 1068.4952.2 1012.4958.0 953.7911.1 0.151
Warfarin 55 (7.0) 36 (4.5) 27 (3.7) 0.010
Warfarin duration, d 1454.31455.9 1100.11213.7 910.31175.6 0.045
P2Y12 284 (35.9) 272 (34.3) 265 (36.0) 0.732
P2Y12 duration, d 1344.11144.5 1377.11144.9 1267.91090.3 0.385
Follow-up duration, d 3087.6669.4 3030.2663.4 2832.6904.0 <0.001
Data are presented as meanSD or number (percentage). Each type of stroke was deﬁned with diagnostic codes, as follows: hemorrhagic stroke, I60 to I62; ischemic stroke, I63; and
unspeciﬁed stroke, I64. BP indicates blood pressure; CCB, calcium channel blocker; DBP, diastolic BP; DM, diabetes mellitus; RASB, renin-angiotensin system blocker; and SBP, systolic BP.
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Table 2. Clinical Characteristics of the Total Study Population According to Observed Mean DBP (N=2320)
Characteristics
Observed Mean DBP, mm Hg
P Value<80 (N=878) 80–<90 (N=1100) ≥90 (N=342)
Types of stroke 0.008
Hemorrhagic 148 (16.9) 209 (19.0) 84 (24.6)
Ischemic 693 (78.9) 850 (77.3) 253 (74.0)
Unspecified 37 (4.2) 41 (3.7) 5 (1.5)
DBP, mm Hg 74.93.9 83.92.6 94.55.4 <0.001
No. of BP measurements 4.51.7 4.62.0 3.72.0 <0.001
Age, y 61.28.6 60.69.3 59.49.9 0.008
Sex 0.001
Male 450 (51.3) 645 (58.6) 207 (60.5)
Female 428 (48.7) 455 (41.4) 135 (39.5)
Residential area 0.498
Metropolitan 299 (34.1) 352 (32.0) 119 (34.8)
Province 579 (65.9) 748 (68.0) 223 (65.2)
Household income 0.095
Upper 20% 264 (30.1) 287 (26.1) 84 (24.6)
Middle 40% 335 (38.2) 441 (40.1) 127 (37.1)
Lower 40% 279 (31.8) 372 (33.8) 131 (38.3)
Smoking status 0.561
Never smoker 608 (69.2) 739 (67.2) 220 (64.3)
Ex-smoker 61 (6.9) 86 (7.8) 29 (8.5)
Current smoker 209 (23.8) 275 (25.0) 93 (27.2)
Alcohol frequency <0.001
Never 589 (67.1) 671 (61.0) 179 (52.3)
2–3 Drinks/mo 94 (10.7) 113 (10.3) 36 (10.5)
1–2 Drinks/wk 86 (9.8) 132 (12.0) 55 (16.1)
3–4 Drinks/wk 52 (5.9) 89 (8.1) 39 (11.4)
Daily 57 (6.5) 95 (8.6) 33 (9.6)
Body mass index, kg/m2 24.22.9 24.43.0 24.83.1 0.009
Total cholesterol, mg/dL 206.946.2 205.241.5 204.941.1 0.638
Fasting glucose, mg/dL 109.254.0 107.046.4 108.960.4 0.609
Baseline SBP, mm Hg 131.616.7 142.117.6 157.920.6 <0.001
Baseline DBP, mm Hg 78.09.3 87.410.0 98.913.0 <0.001
History of DM 60 (6.8) 63 (5.7) 21 (6.1) 0.598
History of atrial fibrillation 30 (3.4) 20 (1.8) 8 (2.3) 0.076
Medications during follow-up
RASBs 607 (69.1) 768 (69.8) 246 (71.9) 0.632
RASB duration, d 1585.71195.8 1621.11217.2 1580.71182.2 0.785
b-Blockers 244 (27.8) 293 (26.6) 120 (35.1) 0.009
b-Blocker duration, d 1006.31115.8 901.41077.0 957.91051.3 0.322
CCBs 603 (68.7) 848 (77.1) 256 (74.9) <0.001
Continued
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lower cumulative all-cause (SBP, log-rank P<0.001 [Fig-
ure 2A]; DBP, P<0.001 [Figure 2B]) and cardiovascular (SBP,
log-rank P<0.001 [Figure 2C]; DBP, P<0.001 [Figure 2D])
deaths in lower BP groups compared with the higher BP
groups (SBP ≥140 mm Hg and DBP ≥90 mm Hg).
Table 3 shows the results of Cox proportional hazard
models for all-cause death, cardiovascular death, detailed
cause of death, and nonfatal events, including MI and stroke,
according to mean SBP. The propensity-adjusted model
revealed that subjects with a mean SBP of 130 to
<140 mm Hg had a signiﬁcantly lower risk of all-cause death
(hazard ratio [HR], 0.61; 95% conﬁdence interval [CI], 0.47–
0.79; P<0.001), cardiovascular mortality (HR, 0.39; 95% CI,
0.25–0.61; P<0.001), and fatal ischemic stroke (HR, 0.25;
95% CI, 0.10–0.63; P=0.003) compared with subjects with a
mean SBP of ≥140 mm Hg. There was no additional beneﬁt
for mean SBP of <130 mm Hg with regard to all-cause or
cardiovascular death. In terms of nonfatal events, the risks of
nonfatal MI and nonfatal ischemic stroke did not differ
according to mean SBP groups. However, the risk of nonfatal
hemorrhagic stroke was signiﬁcantly lower in the mean SBP of
<130 mm Hg group (HR, 0.57; 95% CI, 0.33–0.97; P=0.038)
compared with subjects with a mean SBP of ≥140 mm Hg.
Subjects with a mean DBP of 80 to <90 mm Hg had a
signiﬁcantly lower risk of all-cause death (HR, 0.60; 95% CI,
0.45–0.80; P<0.001) and cardiovascular mortality (HR, 0.45;
95% CI, 0.30–0.70; P<0.001) compared with subjects with a
mean DBP of ≥90 mm Hg (Table 4). Mean DBP of <80 mm Hg
was associated with a signiﬁcantly lower risk of all-cause death
(HR, 0.45; 95% CI, 0.32–0.63; P<0.001), cardiovascular
mortality (HR, 0.29; 95% CI, 0.17–0.49; P<0.001), fatal MI
(HR, 0.04; 95% CI, 0.01–0.28; P=0.001), and fatal hemorrhagic
stroke (HR, 0.21; 95% CI, 0.05–0.92; P=0.039). Mean DBP of
<80 mm Hg was associated with further reduction in all-cause
mortality, cardiovascular mortality, and fatal MI compared with
subjects with a mean DBP of 80 to <90 mm Hg (Table 4).
However, the risk of nonfatal MI was signiﬁcantly higher in
subjects with a mean DBP of <90 mm Hg compared with
subjects with a mean DBP of 80 to <90 mm Hg. Subjects with
a mean DBP of 80 to <90 mm Hg had a trend for lower risk of
nonfatal hemorrhagic stroke (HR, 0.65; 95% CI, 0.40–1.07;
P=0.091), whereas subjects with a mean DBP of <80 mm Hg
were associated with a signiﬁcantly lower risk of nonfatal
hemorrhagic stroke (HR, 0.47; 95% CI, 0.26–0.85; P=0.012).
To exclude the possibility of events being caused by the initial
stroke itself, we performed an additional analysis to exclude
subjects who died within 1 year from the index stroke event
(Tables S7 and S8) and observed a similar trend in clinical
outcomes compared with the original analyses. In addition, we
analyzed the subject regardless of duration of antihypertensive
medication. This also showed similar results (Tables S5 and
S6). Further analysis of the effect of mean SBP of
<120 mm Hg showed a tendency for lower risk of cardiovas-
cular death and fatal ischemic stroke. The risks of both fatal
and nonfatal events were not signiﬁcantly lower in subjects
with a mean SBP of <120 mm Hg compared with subjects
with a mean SBP of ≥140 mm Hg (Table S9). Mean DBP of
<70 mm Hg showed a tendency for reduced risk of cardio-
vascular death, but there was no reduction in risk of other
outcomes (Table S10). When DBP of 80 to <90 mm Hg was
Table 2. Continued
Characteristics
Observed Mean DBP, mm Hg
P Value<80 (N=878) 80–<90 (N=1100) ≥90 (N=342)
CCB duration, d 1634.91263.6 1820.01246.5 1702.41276.6 0.008
Diuretics 209 (23.8) 312 (28.4) 102 (29.8) 0.031
Diuretic duration, d 839.7920.5 796.9883.0 790.3863.3 0.727
Statins 424 (48.3) 452 (41.1) 123 (36.0) <0.001
Statin duration, d 1420.51080.6 1227.11034.5 1263.51091.8 0.006
Aspirin 432 (49.2) 466 (42.4) 132 (38.6) 0.001
Aspirin duration, d 1115.4990.5 966.3910.7 874.4873.9 0.001
Warfarin 58 (6.6) 43 (3.9) 17 (5.0) 0.025
Warfarin duration, d 1376.61428.5 1099.41215.2 939.81252.0 0.184
P2Y12 322 (36.7) 385 (35.0) 114 (33.3) 0.512
P2Y12 duration, d 1334.01150.2 1359.41119.2 1223.81090.3 0.391
Follow-up duration, d 3084.3681.6 2966.0737.0 2805.0947.2 <0.001
Data are presented as meanSD or number (percentage). Each type of stroke was deﬁned with diagnostic codes, as follows: hemorrhagic stroke, I60 to I62; ischemic stroke, I63; and
unspeciﬁed stroke, I64. BP indicates blood pressure; CCB, calcium channel blocker; DBP, diastolic blood pressure; DM, diabetes mellitus; RASB, renin-angiotensin system blocker; and SBP,
systolic blood pressure.
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used as a reference, DBP of 70 to <80 mm Hg had a
signiﬁcantly higher risk of nonfatal MI (Table S10).
Clinical Outcomes According to Mean SBP and
DBP in Subjects Taking Aspirin and/or Statins
During Follow-Up
The clinical characteristics of study subjects who were taking
aspirin or statins are shown in Tables S1 and S2, respectively.
Subjects with a mean SBP of 130 to <140 mm Hg had a
signiﬁcantly lower risk of cardiovascular mortality (HR, 0.39;
95% CI, 0.19–0.81; P=0.012; Table 5) than subjects with a
mean SBP of >140 mm Hg. In terms of DBP, subjects with a
mean DBP of 80 to <90 mm Hg had a signiﬁcantly lower risk
of all-cause death (HR, 0.54; 95% CI, 0.34–0.87; P=0.012),
cardiovascular mortality (HR, 0.28; 95% CI, 0.14–0.60;
P=0.001), and fatal MI (HR, 0.12; 95% CI, 0.02–0.61;
P=0.011) than subjects with a mean DBP of ≥90 mm Hg
(Table 6). Mean DBP of <80 mm Hg was associated with a
signiﬁcantly lower risk of all-cause death, cardiovascular
Figure 2. Kaplan-Meier curves for all-cause death according to mean systolic (A) and diastolic (B) blood pressure levels and for cardiovascular
death according to mean systolic (C) and diastolic (D) blood pressure levels.
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mortality, and fatal MI (Table 6). Mean DBP of <80 mm Hg
was associated with a tendency for further reduction in fatal
MI compared with subjects with a mean DBP of 80 to
<90 mm Hg. However, the risk of nonfatal MI was increased
in subjects with a mean DBP of <80 mm Hg compared with
subjects with a mean DBP of 80 to <90 mm Hg.
Discussion
The key ﬁndings from this study are as follows. First, in
hypertensive subjects with previous stroke, an SBP of
<140 mm Hg was associated with a signiﬁcant reduction in
all-cause mortality, cardiovascular mortality, and fatal
Table 5. Propensity-Adjusted Cox Proportional Hazard Models for Mortality According to Observed Mean SBP Groups in Aspirin
and/or Statin Users
Reference group (≥140) Reference group (130–<140)
Mortality No. (%) of Events HR (95% CI) P Value HR (95% CI) P Value
All-cause death, mm Hg
<130 52 (10.00) 0.97 (0.61–1.53) 0.883 1.41 (0.92–2.17) 0.118
130–<140 43 (8.60) 0.69 (0.45–1.04) 0.077 Reference Reference
≥140 70 (15.35) Reference Reference 1.46 (0.96–2.22) 0.077
Cardiovascular death, mm Hg
<130 19 (3.65) 0.60 (0.28–1.27) 0.180 1.53 (0.71–3.29) 0.274
130–<140 12 (2.40) 0.39 (0.19–0.81) 0.012 Reference Reference
≥140 27 (5.92) Reference Reference 2.57 (1.23–5.38) 0.012
Fatal MI, mm Hg
<130 3 (0.58) 1.15 (0.18–7.53) 0.881 1.99 (0.30–13.10) 0.473
130–<140 2 (0.40) 0.58 (0.09–3.60) 0.558 Reference Reference
≥140 4 (0.88) Reference Reference 1.73 (0.28–10.74) 0.558
Fatal hemorrhagic stroke, mm Hg
<130 1 (0.19) 0.49 (0.03–8.45) 0.627 1.22 (0.07–22.76) 0.892
130–<140 1 (0.20) 0.40 (0.03–4.76) 0.472 Reference Reference
≥140 3 (0.66) Reference Reference 2.47 (0.21–29.16) 0.472
Fatal ischemic stroke, mm Hg
<130 4 (0.77) 0.71 (0.14–3.78) 0.692 2.03 (0.35–11.82) 0.431
130–<140 2 (0.40) 0.35 (0.06–2.10) 0.251 Reference Reference
≥140 4 (0.88) Reference Reference 2.84 (0.48–16.96) 0.251
Nonfatal MI, mm Hg
<130 20 (3.85) 1.69 (0.70–4.04) 0.243 1.87 (0.88–4.00) 0.105
130–<140 12 (2.40) 0.90 (0.38–2.11) 0.809 Reference Reference
≥140 14 (3.07) Reference Reference 1.11 (0.47–2.61) 0.809
Nonfatal hemorrhagic stroke, mm Hg
<130 18 (3.46) 0.60 (0.28–1.29) 0.193 0.96 (0.48–1.93) 0.907
130–<140 18 (3.60) 0.63 (0.32–1.22) 0.171 Reference Reference
≥140 26 (5.70) Reference Reference 1.59 (0.82–3.11) 0.171
Nonfatal ischemic stroke, mm Hg
<130 113 (21.73) 0.82 (0.59–1.15) 0.253 0.92 (0.70–1.22) 0.558
130–<140 114 (22.80) 0.90 (0.67–1.20) 0.459 Reference Reference
≥140 114 (25.00) Reference Reference 1.12 (0.83–1.49) 0.459
All models were adjusted by propensity scores based on age, sex, residential area, household income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting
glucose, baseline SBP, baseline diastolic blood pressure, history of diabetes mellitus, and history atrial ﬁbrillation. CI indicates conﬁdence interval; HR, hazard ratio; MI, myocardial
infarction; and SBP, systolic blood pressure.
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ischemic stroke. Second, an SBP of <130 mm Hg was
associated with a signiﬁcantly lower risk of nonfatal hemor-
rhagic stroke compared with subjects with a mean SBP of
≥140 mm Hg. Third, a DBP of <80 mm Hg was associated
with a further reduction in all-cause mortality, cardiovascular
mortality, and fatal MI compared with subjects with a DBP of
80 to <90 mm Hg. However, there was a signiﬁcant increase
in risk of nonfatal MI. Because the association between BP
and stroke incidence is stronger in Asian populations than
Western populations, the target BP in Asian subjects may
differ from that in other ethnicities.12
The present results differ from the SPS3 study, which
demonstrated an insigniﬁcant beneﬁt of strict SBP control in
reducing the composite outcome of fatal MI or vascular death.
This discrepancy may be related to the 3.7-year mean follow-up
of the SPS3 study, whichmay have been insufﬁcient to discern a
difference in cardiovascular mortality, and limited enrollment to
subjects with previous lacunar infarction. However, the SPS3
study detected a signiﬁcant 63% reduction in intracerebral
hemorrhage, which is consistent with this study, in which mean
SBP of <130 mm Hg, compared with subjects with amean SBP
of ≥140 mm Hg, was associated with a signiﬁcant reduction in
nonfatal hemorrhagic stroke. In addition, mean DBP of
<80 mm Hg showed notable risk reduction for both fatal and
nonfatal hemorrhagic stroke. A previous post-hoc analysis and
meta-analysis have supported the beneﬁt of strict BP control in
hypertensive subjects with stroke. In a subgroup analysis of the
ACCORD BP (Action to Control Cardiovascular Risk in Diabetes
Blood Pressure Trial), intensive BP treatment was associated
with signiﬁcant reduction in both total stroke and nonfatal
stroke.13 In a metaregression analysis of 618 815 participants
in 123 studies, every 10–mm Hg reduction in SBP was
associated with a 27% reduction in stroke risk, regardless of
baseline disease history, suggesting a signiﬁcant beneﬁt of
strict BP lowering.14 In the VALUE (Valsartan Antihypertensive
Long-Term Use Evaluation) study post-hoc analysis, reduction
of on-treatment SBP to <130 mm Hg was only beneﬁcial for
further reduction of stroke risk, without any beneﬁt for
cardiovascular mortality, MI, or congestive heart failure.15
However, some studies have demonstrated a potential for
harm with lower BP. In a community-based study of partic-
ipants from the National Health and Nutrition Examination
Survey (1998–2004) with a self-reported history of stroke, a
baseline SBP <120 mm Hg was associated with higher all-
cause mortality and a trend toward higher vascular mortality
compared with normal SBP (120–140 mm Hg) and high SBP
(>140 mm Hg).16 Our study differs from this previous study in
that we analyzed the difference in cardiovascular mortality risk
according to mean SBP during follow-up rather than baseline
SBP. In addition, our study excluded subjects with concomitant
malignancies or subjects who died within 1 year of the
diagnosis of stroke. These factors may have reduced the
inclusion of subjects in poorer general condition in the present
study, in whom lower baseline BP may be associated with
higher mortality.17,18 The signiﬁcant reductions in both fatal
ischemic and nonfatal hemorrhagic stroke in our study are
supported by the post-hoc analysis of the INVEST (International
Verapamil-Trandolapril Study), which demonstrated a J-shaped
phenomenon for MI but not for fatal or nonfatal stroke.10,19
Also, in the post-hoc analysis of the ONTARGET (Telmisartan
Alone and in Combination With Ramipril Global Endpoint Trial),
a J curve was demonstrated at a mean SBP of <130 mm Hg for
total and cardiovascular mortality and coronary events, but not
for fatal and nonfatal stroke.20 Further analysis of this study did
not reveal an increased risk of clinical outcomes in subjects
with a mean SBP of <120 mm Hg or a mean DBP of
<70 mm Hg compared with subjects with a mean BP of
≥140/90 mm Hg. However, because the number of subjects
with a mean SBP of <120 mm Hg (N=199) or a mean DBP of
<70 mm Hg (N=92) was small, these results should be
interpreted with caution. In a post-hoc analysis of the PROFESS
(Prevention Regimen for Effectively Avoiding Second Strokes)
study, subjects with a mean SBP between 120 and 140 mm Hg
had the lowest risk of recurrent stroke, and subjects with a
mean SBP of <120 mm Hg had an increased risk of recurrent
stroke.21 Also, when we analyzed for the presence of the J curve
with SBP of 130 to <140 mm Hg or DBP of 80 to <90 mm Hg
as reference, we found that DBP of <80 mm Hg was associated
with increased risk of nonfatal MI. It is uncertain why there was a
reduction in fatal MI but an increase in nonfatal MI for subjects
with a mean DBP of <80 mm Hg. It may be that subjects who
have a lower mean DBP have a lower severity of MI or that the
low number of fatal MIs in this analysis was a chance
phenomenon. Another explanation may be the limitation of
ICD-10–based diagnosis of nonfatal events. In a study to
determine the accuracy of acute MI based on ICD codes using
the Korean National Medical Health Insurance claims data, the
accuracy of acute MI was 73.1%, according to the European
Society of Cardiology/American College of Cardiology criteria.22
Several limitations of this study should be discussed. First,
because this study was based on a retrospective cohort
analysis, the results can only be interpreted as hypothesis
generating. However, this study demonstrated that lower
mean BP is associated with a reduction in mortality, cardio-
vascular mortality, and nonfatal strokes in hypertensive
subjects with previous stroke and provides important insight
into the potential beneﬁt of strict BP lowering in this
population. The ongoing SHOT (Systolic Hypertension Optimal
Treatment Trial), a trial enrolling 7500 subjects >65 years with
previous stroke or transient ischemic attack to investigate the
relationship between SBP treatment targets and recurrent
stroke, will help to validate this important issue in hyperten-
sion management.23 Second, because this study was based on
claims data using ICD-10 diagnosis codes, it was limited in
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terms of determining stroke severity. Therefore, we cannot
rule out the confounding effect of stroke severity on the
outcomes of these subjects. Third, we cannot conclude
whether subjects with a relatively well-controlled mean BP
were more compliant with their BP, statin, and aspirin
prescriptions. However, a similar trend was demonstrated in
the Cox regression analysis for subjects taking aspirin and
statins. Fourth, because health examinations supported by the
National Health Insurance Corporation were performed in
various hospitals and clinics, there was a lack of uniformity of
BP measuring devices. Fifth, the study subjects were relatively
young and able to receive the nationwide health examination.
As such, subjects with stroke with more severe disabilities
would more than likely have been omitted from participation.
Table 6. Propensity-Adjusted Cox Proportional Hazard Models for Mortality According to Observed Mean DBP Groups in Aspirin
and/or Statin Users
Reference group (≥90) Reference group (80–<90)
Mortality No. (%) of Events HR (95% CI) P Value HR (95% CI) P Value
All-cause death, mm Hg
<80 64 (10.61) 0.49 (0.29–0.85) 0.011 0.91 (0.62–1.32) 0.618
80–<90 70 (10.29) 0.54 (0.34–0.87) 0.012 Reference Reference
≥90 31 (16.06) Reference Reference 1.84 (1.15–2.96) 0.012
Cardiovascular death, mm Hg
<80 20 (3.32) 0.18 (0.07–0.42) <0.001 0.62 (0.32–1.19) 0.151
80–<90 24 (3.53) 0.28 (0.14–0.60) 0.001 Reference Reference
≥90 14 (7.25) Reference Reference 3.52 (1.68–7.37) 0.001
Fatal MI, mm Hg
<80 1 (0.17) 0.01 (0.00–0.19) 0.001 0.12 (0.01–1.14) 0.065
80–<90 4 (0.59) 0.12 (0.02–0.61) 0.011 Reference Reference
≥90 4 (2.07) Reference Reference 8.61 (1.64–45.13) 0.011
Fatal hemorrhagic stroke, mm Hg
<80 1 (0.17) 0.34 (0.01–10.57) 0.536 0.34 (0.03–4.10) 0.398
80–<90 3 (0.44) 0.98 (0.07–13.60) 0.989 Reference Reference
≥90 1 (0.52) Reference Reference 1.02 (0.07–14.11) 0.989
Fatal ischemic stroke, mm Hg
<80 6 (1.00) 0.43 (0.04–4.93) 0.498 1.31 (0.29–5.82) 0.726
80–<90 3 (0.44) 0.33 (0.03–3.58) 0.362 Reference Reference
≥90 1 (0.52) Reference Reference 3.04 (0.28–33.10) 0.362
Nonfatal MI, mm Hg
<80 24 (3.98) 0.93 (0.34–2.52) 0.886 2.14 (1.04–4.38) 0.038
80–<90 14 (2.06) 0.43 (0.17–1.12) 0.085 Reference Reference
≥90 8 (4.15) Reference Reference 2.30 (0.89–5.92) 0.085
Nonfatal hemorrhagic stroke, mm Hg
<80 22 (3.65) 0.50 (0.21–1.18) 0.114 1.00 (0.53–1.89) 0.991
80–<90 25 (3.68) 0.50 (0.24–1.04) 0.063 Reference Reference
≥90 15 (7.77) Reference Reference 2.00 (0.96–4.13) 0.063
Nonfatal ischemic stroke, mm Hg
<80 141 (23.38) 0.76 (0.51–1.14) 0.190 0.97 (0.75–1.25) 0.800
80–<90 152 (22.35) 0.79 (0.55–1.13) 0.198 Reference Reference
≥90 48 (24.87) Reference Reference 1.27 (0.88–1.81) 0.198
All models were adjusted by propensity scores based on age, sex, residential area, household income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting
glucose, baseline systolic blood pressure, baseline DBP, history of diabetes mellitus, and history atrial ﬁbrillation. CI indicates conﬁdence interval; DBP, diastolic blood pressure; HR, hazard
ratio; and MI, myocardial infarction.
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Therefore, the results from this study cannot be generalized to
the entire stroke population. Sixth, because the inclusion
criteria allowed for subjects who received diagnoses of stroke
and hypertension either simultaneously or separately during
the index period, 1337 were diagnosed as having hypertension
before being diagnosed as having stroke. As such, the mean
BP reﬂects the mean BP of the study population from the start
of the index period rather than after the stroke event. Because
health examinations are performed every 2 years for ofﬁce
workers and annually for manual laborers, a cardiovascular
event within 1 year after stroke will most likely reﬂect the
average BP measured during the index period before the
development of stroke. We cannot rule out the possibility that
BP measured before stroke does not accurately reﬂect BP after
stroke because of more active intervention to lower BP after
the stroke event. In addition, the frequency of health
examination received varied among the study subjects.
However, analyses using the last BP measurement before
mortality, clinical events, or the last health examination
showed a trend to the original results (Tables S11 and S12).
Seventh, 40% of all the subjects with stroke during the index
period had a diagnosis of hypertension. Because the diagnosis
of hypertension was based on the ICD-10 code of claims data
and not on the BP level or prescription of antihypertensive
medications, we cannot rule out the possibility that subjects
with stroke who had hypertension were missed because of
omission of the diagnostic code for hypertension. Because we
had aimed to analyze subjects with stroke who had hyperten-
sion, we believed that the strict inclusion criteria to analyze
only subjects with a diagnosis of hypertension were appropri-
ate. Last, the large difference in the HR for some of the clinical
events, such as fatal MI, may be attributable to the relatively
few events. Also, because this was a retrospective analysis of
an observational cohort, there is a possibility that subjects
with a lower BP may have been more compliant with
medication and lifestyle modiﬁcations, important factors that
may have an additive effect on the HR.
In conclusion, in hypertensive subjects with previous
stroke, a mean DBP of <80 mm Hg was associated with
signiﬁcant beneﬁt in total mortality, cardiovascular mortality,
and some of the nonfatal cardiovascular events. However,
there was an increase in nonfatal MI in subjects with a mean
DBP of <80 mm Hg compared with subjects with a mean DBP
of 80 to <90 mm Hg. Mean SBP of <130 mm Hg was
associated with a signiﬁcantly lower risk of nonfatal hemor-
rhagic strokes. The results from this study require validation
by future randomized clinical trials.
Perspectives
Previously, only the SPS3 study sought to demonstrate the
potential beneﬁt of strict BP control in patients after stroke.
However, because the SPS3 study was performed in patients
after lacunar infarction, the beneﬁt of strict BP lowering in all
hypertensive patients after stroke is not clear. The results
from the present study demonstrate the potential beneﬁt of a
BP of <130/80 mm Hg in hypertensive subjects with prior
stroke. However, the potential risk for increased risk of
nonfatal MI in subjects with a mean DBP of <80 mm Hg was
observed. Also, because this study is based on an observa-
tional cohort, the results from this study are only hypothesis
generating. Nevertheless, the results support the necessity
for future studies to demonstrate the beneﬁt of strict BP
control in all patients with stroke.
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SUPPLEMENTAL MATERIAL 
 
Data S1. 
 
Health examination program provided by the Korean National Health Insurance 
Corporation 
The Korean National Health Insurance Service provides nationwide health examination 
program to improve the health of citizens and reduce their health care costs through the 
prevention of cardio-cerebrovascular diseases affected by lifestyle. Nationwide health 
examination consists of a general and a life-transition health examination.1 Employee 
subscriber, its dependents, regional insurance subscriber who is a regional householder, and 
its family members can receive the general health examination biennially. For non-office 
workers among employee subscribers, this examination is conducted annually. The life-
transition health examination is given to people reaching ages of 40 and 66, who is eligible to 
receive the general health examination.1,2 The National Health Insurance Service health 
examinee cohort (NHIS-HealS) was made with data of nationwide health examinations 
conducted by the NHIS in 2002–13.3  
  
Table S1. Clinical characteristics of aspirin and/or statin users according to observed mean 
systolic blood pressure. 
 
<130 mmHg 
(N=520) 
130 to <140 
mmHg 
(N=500) 
≥140 mmHg 
(N=456) 
P value 
Average SBP, mmHg 122.7±5.9 134.4±2.8 148.9±8.8 <0.001 
Number of BP measurement  4.7±1.8  4.8±1.9  4.1±1.8 <0.001 
Age (year) 58.6±8.5 60.5±9.1 61.7±8.7 <0.001 
Sex, N (%)    0.564 
Male 285 (54.8) 271 (54.2) 262 (57.5)  
Female 235 (45.2) 229 (45.8) 194 (42.5)  
Residential area, N (%)     
Metropolitan 174 (33.5) 162 (32.4) 164 (36.0) 0.493 
Province 346 (66.5) 338 (67.6) 292 (64.0)  
Household income, N (%)     
Upper 20% 161 (31.0) 143 (28.6) 112 (24.6) 0.194 
Middle 40% 200 (38.5) 185 (37.0) 183 (40.1)  
Lower 40% 159 (30.6) 172 (34.4) 161 (35.3)  
Smoking status, N (%)    0.862 
Never smoker 347 (66.7) 346 (69.2) 317 (69.5)  
Ex-smoker 41 (7.9) 36 (7.2) 30 (6.6)  
Current smoker 132 (25.4) 118 (23.6) 109 (23.9)  
Alcohol frequency, N (%)    0.091 
Never 321 (61.7) 317 (63.4) 275 (60.3)  
2~3/month 64 (12.3) 51 (10.2) 39 (8.6)  
1~2/week 67 (12.9) 56 (11.2) 72 (15.8)  
3~4/week 44 (8.5) 36 (7.2) 34 (7.5)  
Daily 24 (4.6) 40 (8.0) 36 (7.9)  
Body mass index, kg/m2 24.4±2.9 24.7±2.8 24.8±3.0 0.141 
Total cholesterol, mg/dL 211.2±40.8 211.8±45.4 211.1±44.0 0.960 
Fasting glucose, mg/dL 107.3±44.0 106.5±37.7 113.6±63.9 0.055 
Baseline SBP, mmHg 128.0±14.1 138.8±15.0 155.6±18.7 <0.001 
Baseline DBP, mmHg 80.0±10.0 84.6±11.4 91.8±12.2 <0.001 
History of DM, N (%) 30 (5.8) 31 (6.2) 31 (6.8) 0.802 
History of atrial fibrillation, 
N (%) 
19 (3.7) 12 (2.4) 5 (1.1) 0.035 
Antihypertensive 
medication  
    
RASB, N (%) 379 (72.9) 398 (79.6) 358 (78.5) 0.024 
RASB duration, day 1712.3±1220.3 1828.6±1190.9 1894.0±1204.1 0.073 
BB, N (%) 151 (29.0) 153 (30.6%) 156 (34.2) 0.208 
BB duration, day 1116.4±1167.5 978.2±1037.8 1022.1±1110.4 0.353 
CCB, N (%) 358 (68.8) 384 (76.8) 375 (82.2) <0.001 
CCB duration, day 1747.7±1283.4 1856.8±1241.7 2014.0±1274.8 0.008 
Diuretics, N (%) 118 (22.7) 174 (34.8) 158 (34.6) <0.001 
Diuretics duration, day 807.0±864.0 935.5±938.7 930.7±934.4 0.227 
Statin, N (%) 362 (69.6) 340 (68.0) 297 (65.1) 0.322 
Statin duration, day 1582.6±1015.4 1599.3±1030.4 1436.9±992.7 0.059 
Aspirin, N (%) 368 (70.8) 340 (68.0) 322 (70.6) 0.565 
Aspirin duration, day 1262.1±931.6 1256.2±939.5 1224.3±889.7 0.825 
Follow-up duration, day 3161.2±576.5 3104.5±532.4 3023.8±668.3 0.001 
Data are presented as mean ± SD or N (%).  
BB, beta blocker; BP, blood pressure; CCB, calcium channel blocker; DBP, diastolic blood 
pressure; DM, diabetes mellitus; RASB, renin angiotensin system blocker; SBP, systolic 
blood pressure.  
Table S2. Clinical characteristics of aspirin and/or statin users according to observed mean 
diastolic blood pressure. 
 
<80 mmHg 
(N=603) 
80 to <90 
mmHg 
(N=680) 
≥90 mmHg 
(N=193) 
P value 
Average DBP, mmHg 126.5±8.9 137.3±8.3 151.8±12.3 <0.001 
Number of BP measurement  4.6±1.7  4.7±2.0  3.9±2.0 <0.001 
Age (year) 60.9±8.4 60.1±9.0 58.6±9.6 0.005 
Sex, N (%)    0.008 
Male 310 (51.4) 385 (56.6) 123 (63.7)  
Female 293 (48.6) 295 (43.4) 70 (36.3)  
Residential area, N (%)     
Metropolitan 199 (33.0) 225 (33.1) 76 (39.4) 0.223 
Province 404 (67.0) 455 (66.9) 117 (60.6)  
Household income, N (%)    0.469 
Upper 20% 184 (30.5) 184 (27.1) 48 (24.9)  
Middle 40% 227 (37.6) 267 (39.3) 74 (38.3)  
Lower 40% 192 (31.8) 229 (33.7) 71 (36.8)  
Smoking status, N (%)    0.223 
Never smoker 430 (71.3) 454 (66.8) 126 (65.3)  
Ex-smoker 44 (7.3) 51 (7.5) 12 (6.2)  
Current smoker 129 (21.4) 175 (25.7) 55 (28.5)  
Alcohol frequency, N (%)     
Never 404 (67.0) 413 (60.7) 96 (49.7) 0.001 
2~3/month 63 (10.4) 70 (10.3) 21 (10.9)  
1~2/week 67 (11.1) 88 (12.9) 40 (20.7)  
3~4/week 33 (5.5) 61 (9.0) 20 (10.4)  
Daily 36 (6.0) 48 (7.1) 16 (8.3)  
Body mass index, kg/m2 24.3±2.9 24.7±2.9 25.2±2.8 <0.001 
Total cholesterol, mg/dL 211.1±43.5 212.0±43.7 210.4±41.8 0.884 
Fasting glucose, mg/dL 109.2±43.8 108.3±47.7 110.4±67.9 0.864 
Baseline SBP, mmHg 131.9±16.5 142.4±17.3 158.6±21.0 <0.001 
Baseline DBP, mmHg 78.2±9.1 87.5±10.1 99.2±12.4 <0.001 
History of DM, N (%) 36 (6.0) 43 (6.3) 13 (6.7) 0.921 
History of atrial fibrillation, 
N (%) 
21 (3.5) 11 (1.6) 4 (2.1) 0.091 
Antihypertensive medication      
RASB, N (%) 441 (73.1) 538 (79.1) 156 (80.8) 0.015 
RASB duration, day 1707.7±1218.9 1873.5±1204.8 1889.5±1159.9 0.040 
BB, N (%) 185 (30.7) 201 (29.6) 74 (38.3) 0.063 
BB duration, day 1073.3±1143.7 988.5±1078.0 1088.3±1089.8 0.525 
CCB, N (%) 423 (70.1) 539 (79.3) 155 (80.3) <0.001 
CCB duration, day 1727.7±1286.6 1953.2±1246.5 2002.5±1271.4 0.004 
Diuretics, N (%) 158 (26.2) 232 (34.1) 60 (31.1) 0.009 
Diuretics duration, day 905.3±929.8 880.1±895.3 936.4±967.8 0.839 
Statin, N (%) 424 (70.3) 452 (66.5) 123 (63.7) 0.154 
Statin duration, day 1627.7±1024.7 1467.5±994.0 1544.0±1045.8 0.043 
Aspirin, N (%) 432 (71.6) 466 (68.5) 132 (68.4) 0.434 
Aspirin duration, day 1305.9±970.3 1215.8±889.3 1176.1±859.0 0.160 
Follow-up duration, day 3160.1±554.4 3076.4±586.2 2991.6±716.4 0.001 
Data are presented as mean ± SD or N (%).  
BB, beta blocker; BP, blood pressure; CCB, calcium channel blocker; DBP, diastolic blood 
pressure; DM, diabetes mellitus; RASB, renin angiotensin system blocker; SBP, systolic 
blood pressure. 
  
Table S3. Propensity-adjusted Cox proportional hazard models for mortality according to 
observed mean SBP groups in study population without baseline atrial fibrillation (<120 
[N=760], 120 to <130 [N=774], ≥120 mmHg [N=728]). 
  
No. of events 
(%) 
HR (95% CI) P value 
All-cause death 
<130 mmHg  100 (13.16) 0.63 (0.47-0.86) 0.003 
130 to <140 
mmHg 
108 (13.95) 0.59 (0.46-0.77) <0.001 
≥140 mmHg  183 (25.14) reference reference 
Cardiovascular 
death 
<130 mmHg 37 (4.87) 0.52 (0.32-0.85) 0.009 
130 to <140 
mmHg 
30 (3.88) 0.37 (0.23-0.58) <0.001 
≥140 mmHg 80 (10.99) reference reference 
Fatal MI 
<130 mmHg 4 (0.53) 0.54 (0.13-2.24) 0.398 
130 to <140 
mmHg 
4 (0.52) 0.42 (0.12-1.46) 0.172 
≥140 mmHg 11 (1.51) reference reference 
Fatal 
hemorrhagic 
stroke 
<130 mmHg 3 (0.39) 0.47 (0.11-2.02) 0.310 
130 to <140 
mmHg 
4 (0.52) 0.38 (0.12-1.26) 0.115 
≥140 mmHg 14 (1.92) reference reference 
Fatal ischemic 
stroke 
<130 mmHg 5 (0.66) 0.19 (0.06-0.62) 0.006 
130 to <140 
mmHg 
5 (0.65) 0.20 (0.07-0.56) 0.002 
≥140 mmHg 20 (2.75) reference reference 
Non-fatal MI 
<130 mmHg 22 (2.89) 1.97 (0.86-4.50) 0.109 
130 to <140 
mmHg 
15 (1.94) 1.11 (0.51-2.41) 0.796 
≥140 mmHg 17 (2.34) reference reference 
Non-fatal 
hemorrhagic 
stroke 
<130 mmHg 35 (4.61) 0.57 (0.34-0.97) 0.040 
130 to <140 
mmHg 
44 (5.68) 0.74 (0.47-1.16) 0.188 
≥140 mmHg 54 (7.42) reference reference 
Non-fatal 
ischemic stroke 
<130 mmHg 163 (21.45) 0.93 (0.71-1.22) 0.601 
130 to <140 
mmHg 
168 (21.71) 0.93 (0.74-1.18) 0.558 
≥140 mmHg 174 (23.90) reference reference 
All models were adjusted by propensity scores based on age, sex, residential area, household 
income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting 
glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of 
diabetes mellitus, and history atrial fibrillation.  
SBP, systolic blood pressure; MI, myocardial infarction. 
  
Table S4. Propensity-adjusted Cox proportional hazard models for mortality according to 
observed mean DBP groups in study population without baseline atrial fibrillation (<80 
[N=848], 80 to <90 [N=1080], ≥90 mmHg [N=334]). 
  
No. of events 
(%) 
HR (95% CI) P value 
All-cause death 
<80 mmHg 122 (14.39) 0.43 (0.31-0.61) <0.001 
80 to <90 mmHg 186 (17.22) 0.59 (0.44-0.78) <0.001 
≥90 mmHg 83 (24.85) reference reference 
Cardiovascular 
death 
<80 mmHg 39 (4.60) 0.26 (0.15-0.45) <0.001 
80 to <90 mmHg 68 (6.30) 0.44 (0.28-0.68) <0.001 
≥90 mmHg 40 (11.98) reference reference 
Fatal MI 
<80 mmHg 2 (0.24) 0.04 (0.01-0.28) 0.001 
80 to <90 mmHg 10 (0.93) 0.31 (0.10-0.95) 0.041 
≥90 mmHg 7 (2.10) reference reference 
Fatal 
hemorrhagic 
stroke 
<80 mmHg 4 (0.47) 0.20 (0.04-0.92) 0.039 
80 to <90 mmHg 9 (0.83) 0.37 (0.13-1.09) 0.072 
≥90 mmHg 8 (2.40) reference reference 
Fatal ischemic 
stroke 
<80 mmHg 8 (0.94) 0.20 (0.06-0.66) 0.008 
80 to <90 mmHg 14 (1.30) 0.36 (0.14-0.94) 0.036 
≥90 mmHg 8 (2.40) reference reference 
Nonfatal MI 
<80 mmHg 26 (3.07) 1.33 (0.54-3.30) 0.532 
80 to <90 mmHg 18 (1.67) 0.58 (0.25-1.36) 0.211 
≥90 mmHg 10 (2.99) reference reference 
Non-fatal 
hemorrhagic 
stroke 
<80 mmHg 40 (4.72) 0.48 (0.26-0.87) 0.016 
80 to <90 mmHg 63 (5.83) 0.65 (0.40-1.06) 0.085 
≥90 mmHg 30 (8.98) reference reference 
Non-fatal 
ischemic stroke 
<80 mmHg 186 (21.93) 0.78 (0.57-1.06) 0.116 
80 to <90 mmHg 237 (21.94) 0.80 (0.61-1.05) 0.106 
≥90 mmHg 82 (24.55) reference reference 
All models were adjusted by propensity scores based on age, sex, residential area, household 
income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting 
glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of 
diabetes mellitus, and history atrial fibrillation.  
DBP, diastolic blood pressure; MI, myocardial infarction. 
 
 
Table S5. Propensity-adjusted Cox proportional hazard models for clinical events according to 
observed mean SBP groups in study population including subjects with antihypertensive 
medication duration <1 year (<120 [N=927], 120 to <130 [N=880], ≥120 mmHg [N=835]). 
  
No. of 
events (%) 
Adjusted HR (95% CI) P value 
All-cause death 
<130 mmHg 150 (16.18) 0.58 (0.45-0.75) <0.001 
130 to <140 mmHg 150 (17.05) 0.57 (0.45-0.71) <0.001 
≥140 mmHg 248 (29.70) reference reference 
Cardiovascular 
death 
<130 mmHg 60 (6.47) 0.52 (0.34-0.78) 0.002 
130 to <140 mmHg 50 (5.68) 0.43 (0.30-0.63) 0.000 
≥140 mmHg 110 (13.17) reference reference 
Fatal MI 
<130 mmHg 6 (0.65) 0.29 (0.09-1.00) 0.050 
130 to <140 mmHg 5 (0.57) 0.29 (0.10-0.87) 0.027 
≥140 mmHg 16(1.92) reference reference 
Fatal 
hemorrhagic 
stroke 
<130 mmHg 9 (0.97) 0.89 (0.32-2.50) 0.823 
130 to <140 mmHg 5 (0.57) 0.36 (0.13-1.04) 0.059 
≥140 mmHg 20 (2.40) reference reference 
Fatal ischemic 
stroke 
<130 mmHg 9 (0.97) 0.20 (0.08-0.49) <0.001 
130 to <140 mmHg 12 (1.36) 0.31 (0.15-0.65) 0.002 
≥140 mmHg 29 (3.47) reference reference 
Non-fatal MI 
<130 mmHg 25 (2.70) 2.01 (0.90-4.50) 0.090 
130 to <140 mmHg 17 (1.93) 1.23 (0.58-2.60) 0.587 
≥140 mmHg 18 (2.16) reference reference 
Non-fatal 
hemorrhagic 
stroke 
<130 mmHg 43 (4.64) 0.63 (0.39-1.03) 0.066 
130 to <140 mmHg 48 (5.45) 0.72 (0.48-1.09) 0.124 
≥140 mmHg 66 (7.90) reference reference 
Non-fatal 
ischemic stroke 
<130 mmHg 198 (21.36) 0.95 (0.74-1.22) 0.695 
130 to <140 mmHg 189 (21.48) 0.94 (0.75-1.18) 0.604 
≥140 mmHg 196 (23.47) reference reference 
All models were adjusted by propensity scores based on age, sex, residential area, household 
income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting 
glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of 
diabetes mellitus, and history atrial fibrillation.  
SBP, systolic blood pressure; MI, myocardial infarction. 
  
Table S6. Propensity-adjusted Cox proportional hazard models for clinical events according to 
observed mean DBP groups in study population including subjects with antihypertensive 
medication duration <1 year (<80 [N=1020], 80 to <90 [N=1230], ≥90 mmHg [N=392]). 
  
No. of 
events (%) 
Adjusted HR (95% CI) P value 
All-cause death 
<80 mmHg 184 (18.04) 0.42 (0.31-0.56) <0.001 
80 to <90 mmHg 245 (19.92) 0.53 (0.42-0.68) <0.001 
≥90 mmHg 119 (30.36) reference reference 
Cardiovascular 
death 
<80 mmHg 67 (6.57) 0.32 (0.20-0.50) <0.001 
80 to <90 mmHg 96 (7.80) 0.45 (0.31-0.65) <0.001 
≥90 mmHg 57 (14.54) reference reference 
Fatal MI 
<80 mmHg 4 (0.39) 0.08 (0.02-0.35) 0.001 
80 to <90 mmHg 14 (1.14) 0.38 (0.15-1.00) 0.050 
≥90 mmHg 9 (2.30) reference reference 
Fatal 
hemorrhagic 
stroke 
<80 mmHg 7 (0.69) 0.25 (0.07-0.81) 0.021 
80 to <90 mmHg 15 (1.22) 0.44 (0.19-1.04) 0.062 
≥90 mmHg 12 (3.06) 0reference reference 
Fatal ischemic 
stroke 
<80 mmHg 13 (1.27) 0.22 (0.09-0.57) 0.002 
80 to <90 mmHg 23 (1.87) 0.40 (0.19-0.84) 0.015 
≥90 mmHg 14 (3.57) reference reference 
Non-fatal MI 
<80 mmHg 30 (2.94) 1.41 (0.59-3.38) 0.439 
80 to <90 mmHg 19 (1.54) 0.59 (0.26-1.34) 0.211 
≥90 mmHg 11 (2.81) reference reference 
Non-fatal 
hemorrhagic 
stroke 
<80 mmHg 47 (4.61) 0.48 (0.28-0.83) 0.009 
80 to <90 mmHg 72 (5.85) 0.64(0.41-1.00) 0.050 
≥90 mmHg 38 (9.69) reference reference 
Non-fatal 
ischemic stroke 
<80 mmHg 223 (21.86) 0.80 (0.60-1.07) 0.135 
80 to <90 mmHg 264 (21.46) 0.80 (0.62-1.03) 0.083 
≥90 mmHg 96 (24.49) reference reference 
All models were adjusted by propensity scores based on age, sex, residential area, household 
income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting 
glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of 
diabetes mellitus, and history atrial fibrillation.  
DBP, diastolic blood pressure; MI, myocardial infarction. 
  
Table S7. Propensity-adjusted Cox proportional hazard models for mortality according to 
observed mean SBP groups in survivors after 1 year from the index stroke (<120 [N=783], 120 
to <130 [N=788], ≥120 mmHg [N=711]). 
  
No. of 
events (%) 
Adjusted HR (95% CI) P value 
All-cause death 
<130 mmHg 98 (12.52) 0.71 (0.52-0.97) 0.032 
130 to <140 
mmHg 
108 (13.71) 0.68 (0.52-0.89) 0.005 
≥140 mmHg 160 (22.54) reference reference 
Cardiovascular 
death 
<130 mmHg 37 (4.73) 0.65 (0.39-1.08) 0.093 
130 to <140 
mmHg 
31 (3.93) 0.47 (0.29-0.75) 0.001 
≥140 mmHg 63 (8.87)  reference reference 
Fatal MI 
<130 mmHg 4 (0.51) 0.67 (0.15-3.05) 0.606 
130 to <140 
mmHg 
3 (0.38) 0.41 (0.10-1.69) 0.216 
≥140 mmHg 8 (1.13) reference reference 
Fatal 
hemorrhagic 
stroke 
<130 mmHg 3 (0.38) 0.66 (0.14-3.13) 0.598 
130 to <140 
mmHg 
4 (0.51) 0.57 (0.16-2.03) 0.383 
≥140 mmHg 9 (1.27) reference reference 
Fatal ischemic 
stroke 
<130 mmHg 3 (0.38) 0.16 (0.04-0.67) 0.012 
130 to <140 
mmHg 
6 (0.76) 0.31 (0.11-0.85) 0.023 
≥140 mmHg 14 (1.97) reference reference 
Non-fatal MI 
<130 mmHg 22 (2.8) 1.95 (0.86-4.45) 0.111 
130 to <140 
mmHg 
16 (2.0) 1.16 (0.54-2.50) 0.699 
≥140 mmHg 17 (2.4) reference reference 
Non-fatal 
hemorrhagic 
stroke 
<130 mmHg 35 (4.5) 0.57 (0.37-0.87) 0.010 
130 to <140 
mmHg 
45 (5.7) 0.74 (0.50-1.11) 0.150 
≥140 mmHg 52 (7.3) reference reference 
Non-fatal 
ischemic stroke 
<130 mmHg 170 (21.7) 0.91 (0.70-1.19) 0.508 
130 to <140 
mmHg 
173 (22.0) 0.91 (0.72-1.15) 0.437 
≥140 mmHg 175 (24.7) reference reference 
All models were adjusted by propensity scores based on age, sex, residential area, household 
income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting 
glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of 
diabetes mellitus, and history atrial fibrillation.  
SBP, systolic blood pressure; MI, myocardial infarction.  
  
Table S8. Propensity-adjusted Cox proportional hazard models for mortality according to 
observed mean DBP groups in survivors after 1 year from the index stroke event (<80 [N=870], 
80 to <90 [N=1086], ≥90 mmHg [N=325]). 
  
No. of 
events (%) 
Adjusted HR (95% CI) P value 
All-cause death 
<80 mmHg 120 (13.79) 0.53 (0.37-0.77) <0.001 
80 to <90 mmHg 177 (16.30) 0.69 (0.51-0.94) 0.020 
≥90 mmHg 69 (21.23) reference reference 
Cardiovascular 
death 
<80 mmHg 39 (4.48) 0.35 (0.19-0.62) <0.001 
80 to <90 mmHg 61 (5.62) 0.50 (0.31-0.81) 0.005 
≥90 mmHg 31 (9.54) reference reference 
Fatal MI 
<80 mmHg 2 (0.23) 0.05 (0.01-0.36) 0.003 
80 to <90 mmHg 8 (0.74) 0.31 (0.09-1.18) 0.073 
≥90 mmHg 5 (1.54) reference reference 
Fatal 
hemorrhagic 
stroke 
<80 mmHg 3 (0.34) 0.16 (0.03-0.90) 0.038 
80 to <90 mmHg 7 (0.64) 0.33 (0.10-1.10) 0.071 
≥90 mmHg 6 (1.85) 0reference reference 
Fatal ischemic 
stroke 
<80 mmHg 7 (0.80) 0.44 (0.10-1.99) 0.289 
80 to <90 mmHg 13 (1.20) 0.73 (0.20-2.70) 0.641 
≥90 mmHg 3 (0.92) reference reference 
Non-fatal MI 
<80 mmHg 27 (3.1) 1.33 (0.54-3.29) 0.533 
80 to <90 mmHg 18 (1.7) 0.57 (0.24-1.32) 0.187 
≥90 mmHg 10 (3.1) reference reference 
Non-fatal 
hemorrhagic 
stroke 
<80 mmHg 40 (4.6) 0.50 (0.31-0.80) 0.004 
80 to <90 mmHg 63 (5.8) 0.64 (0.41-1.00) 0.050 
≥90 mmHg 29 (8.9) reference reference 
Non-fatal 
ischemic stroke 
<80 mmHg 193 (22.2) 0.76 (0.56-1.04) 0.088 
80 to <90 mmHg 242 (22.3) 0.79 (0.60-1.04) 0.089 
≥90 mmHg 83 (25.5) reference reference 
All models were adjusted by propensity scores based on age, sex, residential area, household 
income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting 
glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of 
diabetes mellitus, and history atrial fibrillation.  
DBP, diastolic blood pressure; MI, myocardial infarction. 
 
Table S9. Propensity-adjusted Cox proportional hazard models for clinical events in 4 groups by mean SBP (<120 [N=199], 120 to <130 
[N=592], 130 to <140 [N=793], ≥140 mmHg [N=736]). 
  No. of events (%) 
Adjusted HR 
(95% CI) 
P value 
Adjusted HR (95% 
CI) 
P value 
All-cause death 
<120 mmHg  29 (14.57) 0.76 (0.46-1.23) 0.260 1.23 (0.77-1.98) 0.381 
120 to <130 mmHg  77 (13.01) 0.63 (0.46-0.86) 0.004 1.03 (0.76-1.39) 0.845 
130 to <140 mmHg  113 (14.25) 0.61 (0.47-0.79) <0.001 reference reference 
≥140 mmHg  186 (25.27) reference reference 1.63 (1.26-2.11) <0.001 
Cardiovascular 
death 
<120 mmHg  8 (4.02) 0.46 (0.20-1.09) 0.077 1.18 (0.50-2.76) 0.709 
120 to <130 mmHg  34 (5.74) 0.59 (0.36-0.95) 0.031 1.50 (0.91-2.45) 0.109 
130 to <140 mmHg  33 (4.16) 0.39 (0.25-0.61) <0.001 reference reference 
≥140 mmHg  81 (11.01) reference reference 2.54 (1.64-3.95) <0.001 
Fatal MI 
<120 mmHg  0 (0.00) x x x x 
120 to <130 mmHg  4 (0.68) x x x x 
130 to <140 mmHg  4 (0.50) x x reference reference 
≥140 mmHg  11 (1.49) reference reference x x 
Fatal hemorrhagic 
stroke 
<120 mmHg  1 (0.50) 0.96 (0.07-12.49) 0.978 2.46 (0.18-33.10) 0.496 
120 to <130 mmHg  2 (0.34) 0.41 (0.08-2.07) 0.279 1.04 (0.18-5.89) 0.963 
130 to <140 mmHg  4 (0.50) 0.39 (0.12-1.27) 0.118 reference reference 
≥140 mmHg  14 (1.90) reference reference 2.56 (0.79-8.28) 0.118 
Fatal ischemic 
stroke 
<120 mmHg  1 (0.50) 0.14 (0.02-1.31) 0.085 0.59 (0.06-5.36) 0.637 
120 to <130 mmHg  6 (1.01) 0.26 (0.09-0.75) 0.012 1.06 (0.35-3.23) 0.921 
130 to <140 mmHg  7 (0.88) 0.25 (0.10-0.62) 0.003 reference reference 
≥140 mmHg  21 (2.85) reference reference 4.07 (1.62-10.23) 0.003 
Non-fatal MI <120 mmHg  5 (2.51) 2.03 (0.59-7.01) 0.262 1.72 (0.55-5.37) 0.352 
120 to <130 mmHg  17 (2.87) 1.98 (0.86-4.57) 0.108 1.68 (0.83-3.41) 0.153 
130 to <140 mmHg  16 (2.02) 1.18 (0.55-2.53) 0.668 reference reference 
≥140 mmHg  17 (2.31) reference reference 0.85 (0.39-1.82) 0.668 
Non-fatal 
hemorrhagic stroke 
<120 mmHg  9 (4.52) 0.56 (0.24-1.31) 0.185 0.74 (0.34-1.65) 0.468 
120 to <130 mmHg  26 (4.39) 0.57 (0.33-0.99) 0.046 0.75 (0.46-1.24) 0.259 
130 to <140 mmHg  45 (5.67) 0.76 (0.49-1.18) 0.222 reference reference 
≥140 mmHg  54 (7.34) reference reference 1.32 (0.85-2.05) 0.222 
Non-fatal ischemic 
stroke 
<120 mmHg  5 (2.51) 1.10 (0.74-1.64) 0.626 1.20 (0.83-1.72) 0.336 
120 to <130 mmHg  17 (2.87) 0.88 (0.67-1.16) 0.360 0.95 (0.75-1.21) 0.697 
130 to <140 mmHg  16 (2.02) 0.92 (0.73-1.16) 0.497 reference reference 
≥140 mmHg  17 (2.31) reference reference 1.08 (0.86-1.37) 0.497 
All models were adjusted by propensity scores based on age, sex, residential area, household income, smoking status, alcohol frequency, body 
mass index, total cholesterol, fasting glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of diabetes mellitus, 
and history atrial fibrillation.  
SBP, systolic blood pressure; MI, myocardial infarction. 
 
  
Table S10. Propensity-adjusted Cox proportional hazard models for clinical events in 4 groups by mean DBP (<70 [N=92], 70 to <80 [N=786], 
80 to <90 [N=1100], ≥90 mmHg [N=342]). 
  No. of events (%) 
Adjusted HR 
(95% CI) 
P value 
Adjusted HR (95% 
CI) 
P value 
All-cause death 
<70 mmHg 14 (15.22) 0.76 (0.41-1.41) 0.383 0.98 (0.54-1.75) 0.934 
70 to <80 mmHg 114 (14.50) 0.70 (0.51-0.94) 0.020 0.89 (0.70-1.13) 0.356 
80 to <90 mmHg 191 (17.36) 0.78 (0.60-1.02) 0.065 reference reference 
≥90 mmHg  86 (25.15) reference reference 1.28 (0.98-1.68) 0.065 
Cardiovascular 
death 
<70 mmHg 3 (3.26) 0.34 (0.10-1.16) 0.086 0.59 (0.18-1.96) 0.389 
70 to <80 mmHg 40 (5.09) 0.48 (0.30-0.78) 0.003 0.84 (0.56-1.25) 0.392 
80 to <90 mmHg 71 (6.45) 0.57 (0.38-0.86) 0.007 reference reference 
≥90 mmHg  42 (12.28) reference reference 1.74 (1.17-2.60) 0.007 
Fatal MI 
<70 mmHg 0 (0.00) x x x x 
70 to <80 mmHg 2 (0.25) x x X x 
80 to <90 mmHg 10 (0.91) x x reference reference 
≥90 mmHg  7 (2.05) reference reference x x 
Fatal hemorrhagic 
stroke 
<70 mmHg 0 (0.00) x x \x x 
70 to <80 mmHg 4 (0.51) x x x x 
80 to <90 mmHg 9 (0.82) x x reference reference 
≥90 mmHg  8 (2.34) reference reference x x 
Fatal ischemic 
stroke 
<70 mmHg 1 (1.09) 0.48 (0.05-4.22) 0.507 0.97 (0.12-7.87) 0.976 
70 to <80 mmHg 8 (1.02) 0.36 (0.13-1.00) 0.051 0.73 (0.31-1.75) 0.484 
80 to <90 mmHg 16 (1.45) 0.49 (0.22-1.14) 0.098 reference reference 
≥90 mmHg  10 (2.92) reference reference 2.02 (0.88-4.65) 0.098 
Non-fatal MI <70 mmHg 2 (2.17) 1.09 (0.21-5.56) 0.922 1.67 (0.36-7.75) 0.513 
70 to <80 mmHg 25 (3.18) 1.40 (0.62-3.16) 0.414 2.16 (1.16-4.02) 0.016 
80 to <90 mmHg 18 (1.64) 0.65 (0.29-1.45) 0.294 reference reference 
≥90 mmHg  10 (2.92) reference reference 1.54 (0.69-3.44) 0.294 
Non-fatal 
hemorrhagic stroke 
<70 mmHg 4 (4.35) 0.48 (0.16-1.48) 0.202 0.72 (0.25-2.10) 0.551 
70 to <80 mmHg 36 (4.58) 0.52 (0.30-0.88) 0.015 0.77 (0.51-1.18) 0.233 
80 to <90 mmHg 64 (5.82) 0.67 (0.42-1.05) 0.081 reference reference 
≥90 mmHg  30 (8.77) reference reference 1.50 (0.95-2.37) 0.081 
Non-fatal ischemic 
stroke 
<70 mmHg 17 (18.48) 0.75 (0.43-1.30) 0.301 0.86 (0.51-1.43) 0.555 
70 to <80 mmHg 176 (22.39) 0.89 (0.67-1.18) 0.412 1.02 (0.84-1.25) 0.840 
80 to <90 mmHg 243 (22.09) 0.87 (0.67-1.13) 0.291 reference reference 
≥90 mmHg  87 (25.44) reference reference 1.15 (0.89-1.48) 0.291 
All models were adjusted by propensity scores based on age, sex, residential area, household income, smoking status, alcohol frequency, body 
mass index, total cholesterol, fasting glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of diabetes mellitus, 
and history atrial fibrillation.  
SBP, systolic blood pressure; MI, myocardial infarction. 
Table S11. Propensity-adjusted Cox proportional hazard models for mortality according to SBP 
groups using last BP (<120 [N=718], 120 to <130 [N=633], ≥120 mmHg [N=969]).  
  
No. of 
events (%) 
HR (95% CI) P value 
All-cause 
death 
<130 mmHg  143 (14.8) 0.80(0.64-1.01) 0.066 
130 to <140 mmHg  101 (16.0) 0.76(0.59-0.98) 0.033 
≥140 mmHg  161 (22.4) reference reference 
Cardiovascular 
death 
<130 mmHg 52 (5.4) 0.69(0.48-1.00) 0.052 
130 to <140 mmHg 35 (5.5) 0.64(0.42-0.96) 0.030 
≥140 mmHg 69 (9.6) reference reference 
Fatal MI 
<130 mmHg 6 (0.6) 0.58(0.21-1.65) 0.309 
130 to <140 mmHg 3 (0.5) 0.38(0.10-1.39) 0.145 
≥140 mmHg 10 (1.4) reference reference 
Fatal 
hemorrhagic 
stroke 
<130 mmHg 3 (0.3) 0.27(0.07-1.00) 0.050 
130 to <140 mmHg 7 (1.1) 0.82(0.31-2.13) 0.681 
≥140 mmHg 11 (1.5) reference reference 
Fatal ischemic 
stroke 
<130 mmHg 6 (0.6) 0.23(0.09-0.58) 0.002 
130 to <140 mmHg 7 (1.1) 0.42(0.18-0.98) 0.046 
≥140 mmHg 22 (3.1) reference reference 
Non-fatal MI 
<130 mmHg 30 (3.1) 1.37(0.75-2.50) 0.304 
130 to <140 mmHg 7 (1.1) 0.44(0.18-1.05) 0.065 
≥140 mmHg 18 (2.5) reference reference 
Non-fatal 
hemorrhagic 
stroke 
<130 mmHg 51 (5.3) 0.87(0.58-1.32) 0.526 
130 to <140 mmHg 40 (6.3) 1.04(0.67-1.60) 0.865 
≥140 mmHg 43 (6.0) reference reference 
Non-fatal 
ischemic 
stroke 
<130 mmHg 218 (22.5) 1.12(0.91-1.38) 0.285 
130 to <140 mmHg 147 (23.2) 1.10(0.88-1.38) 0.419 
≥140 mmHg 158 (22.0) reference reference 
All models were adjusted by propensity scores based on age, sex, residential area, household 
income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting 
glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of 
diabetes mellitus, and history atrial fibrillation.  
SBP, systolic blood pressure; MI, myocardial infarction. 
 
  
Table S12. Propensity-adjusted Cox proportional hazard models for mortality according to 
DBP groups using last BP (<80 [N=978], 80 to <90 [N=871], ≥90 mmHg [N=471]).  
  
No. of events 
(%) 
HR (95% CI) P value 
All-cause 
death 
<80 mmHg 158 (18.1) 0.79(0.61-1.03) 0.080 
80 to <90 mmHg 98 (20.8) 0.94(0.73-1.22) 0.657 
≥90 mmHg 49 (5.01) reference reference 
Cardiovascular 
death 
<80 mmHg 61 (7.0) 0.59(0.39-0.89) 0.011 
80 to <90 mmHg 46 (9.8) 0.82(0.55-1.20) 0.301 
≥90 mmHg 1 (0.1) reference reference 
Fatal MI 
<80 mmHg 10 (1.2) 0.06(0.01-0.50) 0.009 
80 to <90 mmHg 8 (1.7) 0.76(0.29-1.94) 0.560 
≥90 mmHg 4 (0.4) reference reference 
Fatal 
hemorrhagic 
stroke 
<80 mmHg 10 (1.2) 0.36(0.10-1.26) 0.111 
80 to <90 mmHg 7 (1.5) 0.92(0.35-2.44) 0.866 
≥90 mmHg 12 (1.2) reference reference 
Fatal ischemic 
stroke 
<80 mmHg 10 (1.6) 0.46(0.21-1.03) 0.060 
80 to <90 mmHg 13 (2.8) 0.47(0.20-1.07) 0.073 
≥90 mmHg 26 (2.7) reference reference 
Non-fatal MI 
<80 mmHg 16 (1.8) 1.31(0.72-2.37) 0.380 
80 to <90 mmHg 13 (2.8) 0.44(0.18-1.06) 0.067 
≥90 mmHg 40 (4.1) reference reference 
Non-fatal 
hemorrhagic 
stroke 
<80 mmHg 64 (7.3) 0.91(0.60-1.37) 0.643 
80 to <90 mmHg 30 (6.4) 1.05(0.68-1.62) 0.823 
≥90 mmHg 221 (22.6) reference reference 
Non-fatal 
ischemic 
stroke 
<80 mmHg 190 (21.8) 1.08(0.88-1.33) 0.442 
80 to <90 mmHg 112 (23.8) 1.08(0.86-1.35) 0.500 
≥90 mmHg 158 (18.1) reference reference 
All models were adjusted by propensity scores based on age, sex, residential area, household 
income, smoking status, alcohol frequency, body mass index, total cholesterol, fasting 
glucose, baseline systolic blood pressure, baseline diastolic blood pressure, history of 
diabetes mellitus, and history atrial fibrillation.  
DBP, diastolic blood pressure; MI, myocardial infarction. 
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